XHXinyu He

Xinyu He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Xinyu He has a total of 39 co-authors. Here are the top co-authors by number of shared publications:

  • Kangdong Liu

    Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China; China-US Hormel (Henan) Cancer Institute, Zhengzhou, Henan, China

    3 shared publications
  • Zigang Dong

    Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China

    3 shared publications
  • Dengyun Zhao

    State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Yanan Jiang

    Zhengzhou University

    2 shared publications
  • Yubing Zhou

    State Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer; School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, China

    2 shared publications
  • Fukuan Du

    Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China

    1 shared publication

Latest Publications

  • The emerging roles of alternative splicing in modulating tumor immune responses and immunotherapies

    by Xinyu He, Dengyun Zhao, Yubing Zhou, Yanan Jiang, Zigang Dong, Kangdong Liu

    Alternative splicing is a fundamental mechanism that expands transcriptomic and proteomic diversity and contributes to multiple biological processes, including immune regulation. Increasing evidence shows that dysregulated alternative splicing influences tumor immunogenicity, the immune landscape of the tumor microenvironment, and responses to cancer immunotherapy. Alternative splicing can alter the expression and peptide repertoire of tumor antigens, modulate major histocompatibility complex-mediated antigen presentation, and generate immunomodulatory isoforms that promote immune evasion. In addition, cell type-specific splicing programs regulate the phenotypes and functions of intratumoral immune and stromal cells, including T cells, antigen-presenting cells, myeloid cells, and fibroblasts. Splicing signatures and isoform-level alterations are also associated with clinical responses to immunotherapy, particularly immune checkpoint blockade. A better understanding of splicing dysregulation in tumor immunity may improve biomarker development, patient stratification, and therapeutic targeting of aberrant RNA processing. Overall, alternative splicing is an important regulator of tumor-immune interactions and a potential target in cancer immunotherapy.

  • Open Access

    FBL promotes hepatocellular carcinoma tumorigenesis and progression by recruiting YY1 to enhance CAD gene expression

    by Yafei Zhi, Yan Guo, Shiliang Li, Xinyu He, Huifang Wei, Kyle Laster, Qiong Wu, Dengyun Zhao, Jinxin Xie, Shanshan Ruan, et al.

    Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death worldwide. Accumulating evidence suggests that epigenetic dysregulation contributes to the initiation and progression of HCC. We aimed to investigate key epigenetic regulators that contribute to tumorigenesis and progression, providing a theoretical basis for targeted therapy for HCC. We performed a comprehensive epigenetic analysis of differentially expressed genes in LIHC from the TCGA database. We identified fibrillarin (FBL), an rRNA 2′-O-methyltransferase, as an essential contributor to HCC. A series of in vitro and in vivo biological experiments were performed to investigate the potential mechanisms of FBL. FBL knockdown suppressed the proliferation of HCC cells. In vivo studies using cell-derived xenograft (CDX), patient-derived xenograft (PDX), and diethylnitrosamine (DEN)-induced HCC models in Fbl liver-specific knockout mice demonstrated the critical role of FBL in HCC carcinogenesis and progression. Mechanistically, FBL regulates the expression of CAD in HCC cells by recruiting YY1 to the CAD promoter region. We also revealed that fludarabine phosphate is a novel inhibitor of FBL and can inhibit HCC growth in vitro and in vivo. The antitumor activity of lenvatinib has been shown to be synergistically enhanced by fludarabine phosphate. Our study highlights the cancer-promoting role of the FBL-YY1-CAD axis in HCC and identifies fludarabine phosphate as a novel inhibitor of FBL.


  • Open Access

    Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances

    by Xiang Wang, Zijun Yuan, Zhengbo Li, Xinyu He, Yinping Zhang, Xingyue Wang, Jiahong Su, Xu Wu, Mingxing Li, Fukuan Du, et al.

    The incidence of hepatocellular carcinoma (HCC) ranks first among primary liver cancers, and its mortality rate exhibits a consistent annual increase. The treatment of HCC has witnessed a significant surge in recent years, with the emergence of targeted immune therapy as an adjunct to early surgical resection. Adoptive cell therapy (ACT) using tumor-infiltrating lymphocytes (TIL) has shown promising results in other types of solid tumors. This article aims to provide a comprehensive overview of the intricate interactions between different types of TILs and their impact on HCC, elucidate strategies for targeting neoantigens through TILs, and address the challenges encountered in TIL therapies along with potential solutions. Furthermore, this article specifically examines the impact of oncogenic signaling pathways activation within the HCC tumor microenvironment on the infiltration dynamics of TILs. Additionally, a concise overview is provided regarding TIL preparation techniques and an update on clinical trials investigating TIL-based immunotherapy in solid tumors.


  • Repurposed pizotifen malate targeting NRF2 exhibits anti-tumor activity through inducing ferroptosis in esophageal squamous cell carcinoma

    by Xinyu He, Yubing Zhou, Wenjing Chen, Xiaokun Zhao, Lina Duan, Hao Zhou, Mingzhu Li, Yin Yu, Jimin Zhao, Yaping Guo, et al.

    Targeted therapy attempts are needed to enhance esophageal squamous cell carcinoma (ESCC) patients’ overall survival and satisfaction of life. Nuclear factor erythroid 2-related factor 2 (NRF2), as a high-confidence cancer driver gene, controls the antioxidant response, metabolic balance and redox homeostasis in cancer and is regarded as a potent molecular target for cancer treatment. Here, we attempted to find a new NRF2 inhibitor and study the underlying molecular mechanism in ESCC. We found that up-regulated NRF2 protein was negatively correlated with patient prognosis and promoted tumor proliferation in ESCC. Moreover, Pizotifen malate (PZM), a FDA-approved medication, bound to the Neh1 domain of NRF2 and prevented NRF2 protein binding to the ARE motif of target genes, suppressing transcription activity of NRF2. PZM treatment suppressed tumor development in ESCC PDX model by inducing ferroptosis via down-regulating the transcription of GPX4, GCLC, ME1 and G6PD. Our study illustrates that the over expression of NRF2 indicates poor prognosis and promotes tumor proliferation in ESCC. PZM, as a novel NRF2 inhibitor, inhibits the tumor growth by inducing ferroptosis and elucidates a potent NRF2-based therapy strategy for patients with ESCC.